Letter from the CEO
In my initial 100 days as CEO, I have been creating a roadmap for SciBase's rapid transition into a robust commercial company. I am impressed by the work that has been done so far, but I am at the same time confident that with a more focused approach, we can significantly enhance value for our shareholders, the healthcare sector, and patients.Establishing Nevisense as the standard of care in the U.S. market is my primary objective. This market accounts for three-quarters of our addressable market making it the territory with the highest potential. With the success in Germany, we have shown